A
Allogene Therapeutics
A biotechnology company catalyzing cancer treatment through the development of CAR T therapy
At a glance
- Status
- Listed
- Listing
- IPO 2018
Knowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in United States
Analysis
Serial unicorn founders from Israel
Nov 13, 2026
Open roles
Allogene Therapeutics in the San Francisco ecosystem
The Allogene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
TPG- PFPfizer
- TRTwo River
- VVVida Ventures
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Patents
67 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Allogene Therapeutics was the backer or acquirer, 2021–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Allogene Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Allogene Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Allogene Therapeutics's portfolio, mapped.
See Allogene Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Allogene wins FDA RMAT and Fast Track for cema-cel in first-line large B-cell lymphoma